Medicine & Health

The aging brain doesn't passively decay—it executes a structured, multi-phase eviction protocol. Current evidence supports active clearance of senescent neural stem cells and neuroblasts via NK cell recruitment mediated by the senescence-associated secretory phenotype (SASP)1. But for mature neurons, the mechanism shifts from physical removal to functional isolation.

The Hypothesis: A dual-system emerges with age. First, a targeted immune-clearance tier removes senescent precursors to prevent oncogenic transformation and preserve niche function. Second, a metabolic efficiency tier selectively downregulates and structurally isolates mature neurons that violate energy constraints, without necessarily killing them immediately. This is eviction via silencing, not immediate execution.

Mechanistic Bridge: Senescent glial cells drive neuroinflammation via SASP, activating complement and microglial phagocytic signaling2. But this same inflammatory environment can trigger synaptic stripping—microglial-mediated removal of synapses from otherwise intact neurons3. A neuron with broken mTORC1 nutrient sensing4 and failed proteostasis becomes metabolically expensive to maintain. The system doesn't kill it outright; it first silences it by stripping its connections, reducing its network influence and energy draw.

**Testable Pred

Recent evidence shows that ATF6 activity declines with age while IRE1α and PERK become hyperactivated, shifting the UPR from adaptive to pro-apoptotic [PMC11524792]. Loss of ATF6α triggers sustained IRE1α autophosphorylation and PERK activation [PMC10011727], establishing ATF6 decline as a key driver of pathological UPR imbalance. Yet, the root cause of ATF6 downregulation in aging human tissues remains unclear. I propose that tissue-specific epigenetic silencing of ATF6, through promoter methylation or histone modifications, is the primary trigger for age-related UPR dysfunction, leading to chronic stress and senescence.

Mechanistically, aging may induce hypermethylation of the ATF6 gene promoter or repressive histone marks (e.g., H3K27me3) in a cell-type-dependent manner. This epigenetic repression would reduce ATF6 transcription, diminishing its protein levels and disrupting the stoichiometry of UPR complexes. Without sufficient ATF6, the compensatory crosstalk where IRE1 sustains PERK via XBP1s [PMC11026449] becomes dysregulated, creating a feedforward loop that amplifies IRE1α/PERK signaling. ATF6 normally buffers this by promoting adaptive responses; its loss tips the balance toward apoptosis, as seen in aged skeletal muscle with elevated BiP and CHOP [PMC11524792].

This hypothesis explains tissue-specific variations: different epigenetic landscapes across organs could dictate which UPR arms are affected. For example, in aged epidermis, IRE1-XBP1s declines [onlinelibrary.wiley.com], possibly due to unique chromatin states that also suppress ATF6, while in glioma

The seed idea frames autophagy as a rationing system under siege, not a cleaning crew. AKG's dual action—inhibiting mTOR (triggering autophagy) and fueling TET enzymes (driving DNA demethylation)—suggests a deeper link: autophagy may selectively degrade proteins and complexes that maintain the aged epigenetic state, creating a permissive environment for TET-mediated rejuvenation. This isn't just resource rationing; it's targeted demolition of epigenetic noise before TET can rewrite the methylome.

Mechanistic Insight: Chronic cellular stress (e.g., nutrient shifts, inflammation) leads to accumulation of dysfunctional proteins, organelles, and possibly even methylated histones or repressive chromatin remodelers that "lock" aged gene expression patterns. Standard autophagy clears damaged components for energy. AKG-induced autophagy, however, might be programmed by the concurrent TET flux: demethylation of autophagy-related genes (like ATG5, TFEB) could shift autophagy from general recycling to targeted degradation of epigenetic maintenance factors (e.g., DNMTs, HDACs, or specific histone methyltransferases) [https://pmc.ncbi.nlm.nih.gov/articles/PMC10134649/]. This would clear the way for TETs to access and oxidize 5mC sites previously protected by repressive complexes.

The siege is real—mTOR inhibition signals severe resource pressure. But AKG doesn't just help you survive it; it uses the siege to force a purge of epigenetic baggage. The cell, in rationing mode, cannibalizes the very machinery that perpetuates its aged state. Once cleared, the TET cofactor AKG can

Background

Interstitial lung disease (ILD) associated with autoimmune conditions shares pathological features with aging lungs: fibrosis, telomere shortening, cellular senescence, and stem cell exhaustion. Recent evidence suggests that autoimmune-associated ILD may represent accelerated organ-specific aging rather than simply immune-mediated damage.

Hypothesis

Autoimmune-associated ILD represents a model of accelerated organ-specific senescence, where chronic immune activation drives premature lung aging through telomere attrition, senescent cell accumulation, and fibrotic remodeling. In Maya-mestizo populations with distinct genetic backgrounds (near-absent TYK2 protection, unique TERT biology), this process may follow different kinetics than in European populations — potentially explaining the dominance of NSIP over UIP patterns observed in this cohort.

Preliminary Data

95 consecutive patients with autoimmune-associated ILD at a tertiary hospital in southeastern Mexico. Key longevity-relevant findings:

The Aging Signal

• Mean age: 67.7 years (range 22-83)
• 57% are pensioned/disabled — profound functional decline
• 1 documented death (75-year-old male, RA since 1992, FR+, fibrotic pattern with 40% upper lobe involvement, lost to follow-up since 2022)

The strain-dependent differences in HNE/MDA adduct accumulation between C57BL/6 and DBA/2 mice are well-documented, but why these occur has remained unclear. The inner mitochondrial membrane phospholipid cardiolipin (CL) might hold the answer. CL acyl chain composition could determine both the magnitude of age-related lipid electrophile adduct formation and the downstream senescent phenotype, providing a fundamental molecular basis for strain-specific aging trajectories.

Mechanistic Basis: CL is uniquely enriched in the inner mitochondrial membrane where it organizes respiratory supercomplexes and stabilizes protein complexes. What makes this interesting is that CL contains linoleic acid (18:2) as its predominant fatty acyl chain in many tissues, leaving it unusually vulnerable to peroxidation due to its bis-allylic double bonds. I suspect that C57BL/6 mice carry CL species with longer-chain or more highly unsaturated fatty acyls (20:4, 22:6) compared to DBA/2 mice, creating a richer substrate pool for lipid peroxidation initiation.

This compositional difference would produce three cascading effects. First, enhanced electrophile generation - more CL peroxidation means more HNE and MDA produced. Second, altered membrane architecture - modified CL "lipid whiskers" could disproportionately disrupt CL-rich microdomains where Complex II and ATP synthase are located, amplifying structural dysfunction beyond simple catalytic inactivation. Third, differential partitioning of quality control proteins - changed membrane phase boundaries may sequester or release mitochondrial pr

Hypothesis

Targeted Maximum Likelihood Estimation (TMLE) combined with Super Learner ensemble prediction, applied to longitudinal observational rheumatology cohorts with time-varying confounders (disease activity, comorbidities, concomitant medications), can identify optimal dynamic treatment regimes (DTRs) for biologic sequencing in rheumatoid arthritis that reduce 12-month Sharp/van der Heijde radiographic progression scores by >30% compared to current guideline-driven static treatment protocols.

Background and Rationale

Current rheumatoid arthritis treatment follows a step-up paradigm guided by composite disease activity scores (DAS28, CDAI), but these protocols treat patients as exchangeable within risk strata and do not formally account for time-varying confounding affected by prior treatment — a well-documented source of bias in observational treatment comparisons. Marginal structural models (MSMs) with inverse probability weighting partially address this but suffer from practical positivity violations and weight instability in high-dimensional covariate spaces.

TMLE offers a doubly-robust, semiparametric efficient alternative that combines:

1. Super Learner — a cross-validated ensemble of machine learning algorithms (gradient boosting, random forests, LASSO, neural networks) for initial outcome and treatment mechanism estimation
2. Targeted bias reduction — a fluctuation step that targets the specific causal parameter of interest (here, the counterfactual mean outcome under candidate DTRs)
3. Valid statistical inference — influence function-base

Background

Rare adverse events (AEs) in rheumatology trials — serious infections, malignancy, cardiovascular events under biologics — are typically modeled as homogeneous Poisson processes, assuming constant hazard rates across the trial period. This assumption systematically underestimates clustering risk: AEs tend to aggregate in temporal windows driven by latent immunological states (e.g., transient lymphopenia, complement consumption troughs, or corticosteroid taper-induced rebound).

Hypothesis

Modeling rare AEs in rheumatology trials as doubly stochastic Poisson processes (Cox processes), where the intensity function λ(t) is itself a stochastic process driven by latent immunological covariates, will:

1. Detect AE clustering that standard Poisson models miss, identifying 2–4 temporal vulnerability windows per trial arm
2. Improve AE rate estimation by 20–40% in mean squared error versus homogeneous Poisson baselines
3. Reveal shared latent intensity drivers across different AE categories (infection, cardiovascular, malignancy) via shared frailty components in the Cox process specification
4. Enable real-time adaptive safety monitoring through online Bayesian updating of the latent intensity surface

Proposed Model

Let N(t) be the counting process for AEs. Under the Cox process:

The Proteostatic Paradox

We’ve seen Indole-3-Propionic Acid (IPA) emerge as a heavy-hitting geroprotector in recent studies. It extends Drosophila lifespan and slows down several hallmarks of aging in mice, from heart fibrosis and skeletal decline to Aβ-driven neuroinflammation [10.1126/sciadv.adw8410]. Still, the "IPA Enigma" remains: is this molecule a causal driver of longevity or just a byproduct of a healthy, diverse microbiome? While preclinical data points toward things like autophagy restoration and macrophage repolarization [10.1038/s41467-020-15119-w], we’re still missing a single theory that explains how a gut-derived metabolite exerts such massive systemic influence over the epigenetic clock.

The

Hypothesis: IPA as a Biased AhR-NRF2 Agonist

I suspect IPA functions as a "biased" ligand for the Aryl Hydrocarbon Receptor (AhR). Essentially, it decouples the usual AhR stress response from NRF2-mediated proteostatic signaling. Other indoles, like indoxyl sulfate, act as uremic toxins because they trigger sustained CYP1A1 expression and oxidative stress. IPA is different; it seems to recruit co-activators that favor the AhR-NRF2-autophagy axis instead. This signaling shift builds a state of "metabolic resilience," acting as a proteostatic buffer in tissues that don't regenerate much, like the brain and heart.

I'll go a step further: IPA levels aren't just a marker of current health; they determine the actual slope of biological aging. People with high IPA levels over time should show a much slower rate of change in second-generation epigenetic clock

The research context establishes that autophagic pathways compete for limited ATG machinery in aging endothelium, with oxidized lipids hijacking priority away from mitophagy [doi.org/10.1016/j.ajpath.2013.04.028]. This is a critical insight, but it's incomplete. It treats hierarchy as a static resource allocation problem—like a budget overrun—where lipophagy and ER-phagy simply outspend mitophagy. The mechanistic gap is time. Autophagic selectivity isn't just a priority list; it's a temporally encoded sequence. We propose that healthy vascular endothelium maintains a strict "triage timer": a rapid, initial wave of mitophagy to clear oxidative damage, followed by a slower, sustained phase of ER-phagy/lipophagy for remodeling. Aging and oxidized lipids don't just alter the priority—they corrupt the timer, desynchronizing the sequence and creating pathological interference between pathways.

Here's the novel mechanism: The initiation machinery (ULK1 complex, phagophore formation) is the shared, rate-limiting bottleneck. In youth, mitophagy receptors like FUNDC1 or BNIP3L have higher affinity or are pre-positioned to "claim" nascent autophagosomes first, creating a temporal dominance window for mitochondrial clearance. Oxidized lipids, particularly 7-ketocholesterol, alter this by directly modifying the activity of key ATG proteins [doi.org/10.1016/j.ajpath.2013.04.028]. Our hypothesis centers on Atg4B, the protease that processes LC3 and is inhibited by lipid-induced H₂O₂. We propose Atg4B inhibition doesn't just blunt autophagy globally; it **slows the lipidat

Looking at what we know about collagen deposition, TGF-β signaling, hypoxia, and macrophage crosstalk driving adipose fibrosis, I've come to think that YAP/TAZ mechanotransduction sits at the top of this cascade—acting as a master switch that kicks off fibrotic remodeling before inflammation ever shows up. If this holds up, it's a genuinely new therapeutic angle for tackling established fibrosis.

How This Might Work

Sun et al. described the foreign body reaction with macrophage giant cells forming around adipocytes, but nobody's nailed down what actually triggers that response. Here's my take: as adipocytes expand, they pull against the surrounding extracellular matrix, generating mechanical tension that switches on YAP/TAZ in both the adipocytes themselves and nearby stromal cells. Once activated, this creates a self-perpetuating loop where mechanical stress keeps feeding fibrotic changes.

When adipocytes hypertrophy during early obesity or aging, they bump up against physical constraints from the ECM—that's the tension that drives YAP/TAZ into the nucleus, where it turns on collagen I, III, and VI, α-SMA, and TGF-β. The kicker is that YAP/TAZ activation in adipocytes also sparks production of inflammatory cytokines (IL-6, TNF-α) and chemokines like CCL2 that bring in macrophages. So the fibrosis signaling actually comes first, then inflammation follows.

What We Could Test

1. Timing: In diet-induced obesity mouse models, I'd expect to see YAP/TAZ showing up in adipocyte and stromal cell nuclei within 2-4 weeks—well before we see meaningful macrophage infiltr

Partial epigenetic reprogramming using cyclic expression of Yamanaka factors (specifically OSK—OCT4, SOX2, KLF4) has been hailed as the "fountain of youth," bolstered by recent 2024 data showing a 109% extension of remaining lifespan in 124-week-old wild-type mice.

However, I propose a highly controversial counter-hypothesis: the observed "rejuvenation" is largely a transient phenotypic masking effect that does not repair foundational DNA damage, but instead creates brief, recurring windows of extreme genomic vulnerability.

Critics correctly point out that OSK factors bind to oncogenic promoters (over 20% overlap) and temporarily suppress tumor suppressors like P53 to enable cell cycle reactivation. Proponents argue that omitting c-MYC and using "pulsed" (on/off) delivery mitigates this risk (no tumors reported in the 124-week mouse study).

My hypothesis is that this "pulsed" approach is essentially playing Russian Roulette with clonal expansion. Each pulse forces a transient dedifferentiation state that temporarily lowers the P53 barrier. While the mice did not live long enough post-treatment to develop macroscopic tumors, the repetitive suppression of P53 in an aged genomic environment (which already contains high baseline DNA damage and senescent cells) is mathematically certain to eventually allow a pre-malignant clone to escape.

Furthermore, the rapid reversion of aging markers post-induction suggests we are merely resetting the readout (DNA methylation clocks) rather than fixing the underlying machinery (telomere attrition, double-strand breaks). Are we actu

Hypothesis: The cfDNA methylation clock, while correlating strongly with chronological age, primarily measures cumulative stress-induced cellular damage rather than intrinsic biological aging. Hormetic interventions (e.g., fasting, exercise) may reset these clocks by triggering acute stress responses, but this does not necessarily extend true lifespan, highlighting a dissociation between aging biomarkers and longevity mechanisms.

Mechanistic Rationale: Recent studies demonstrate that cfDNA methylation patterns serve as robust aging biomarkers, with a 48-CpG-site model achieving r = 0.994 correlation [https://pmc.ncbi.nlm.nih.gov/articles/PMC11318736/]. However, these patterns are linked to inflammatory pathways: cfDNA acts as a damage-associated molecular pattern (DAMP) that activates TLR9-mediated immune responses [https://pmc.ncbi.nlm.nih.gov/articles/PMC11318736/]. This indicates that cfDNA changes are reactive to cellular stress and death, not constitutive adaptations for longevity. For instance, elevated cfDNA concentrations correlate with age (r = 0.486), and differentially methylated CpG sites are associated with genes like H1-2 and HNRNPA0, involved in stress responses [https://pmc.ncbi.nlm.nih.gov/articles/PMC11318736/].

The seed idea posits that hormesis works by convincing cells they are about to die, implying that the biology of thriving is indistinguishable from that of near-death stress. If cfDNA methylation patterns reflect stress responses, then hormetic interventions should induce transient changes in these patterns. For example, cold exposure

The prevailing model posits that adipose tissue dysfunction drives systemic inflammation via soluble factors like IL-6 and TNFα (1, 2). This 'source' model is supported but incomplete. We propose that adipose tissue—particularly visceral depots—actively packages its inflammatory signal into extracellular vesicles (EVs), which act as targeted, stable vectors for metabolic disruption in distant organs. This reframes the pathology from passive leakage to active, directed communication.

Mechanistic Reasoning:

1. Signal Amplification & Specificity: Soluble cytokines are promiscuous and rapidly degraded. Adipose-derived EVs, however, can carry a concentrated cargo of SASP factors (IL-1β, TNFα), miRNAs, and damaged mitochondria, delivering them directly to recipient hepatocytes, myocytes, or endothelial cells. This explains the targeted organ damage (e.g., hepatic steatosis) (3) that systemic dilution alone cannot account for. The cargo could include specific miRNAs that reprogram recipient cell metabolism toward a senescent or insulin-resistant state.
2. Cellular Crosstalk Amplifier: The reported age-associated reprogramming of γδ T cells (1) and M1 macrophage polarization (4) within fat likely alters the EV secretion profile. Inflammatory immune cells are prolific EV producers. Thus, the 'immune war' is encoded not just in soluble s

Background

Biologic failure in ankylosing spondylitis (AS) remains clinically unpredictable. Current approaches model treatment response as deterministic dose-response curves, ignoring the inherent stochasticity of immune dynamics. We propose applying Malliavin calculus — the stochastic calculus of variations — to identify pharmacodynamic fragility points: patient-specific parameter sensitivities in the treatment response trajectory that signal impending loss of efficacy.

Hypothesis

We hypothesize that computing the Malliavin derivative of ASDAS (Ankylosing Spondylitis Disease Activity Score) trajectories modeled as solutions to pharmacokinetic-pharmacodynamic SDEs will reveal patient-specific sensitivity coefficients that:

1. Identify which stochastic perturbations (cytokine fluctuations, drug clearance variability, microbiome shifts) most strongly influence treatment trajectories
2. Detect fragility regimes — time windows where small perturbations produce disproportionate trajectory divergence — 8–16 weeks before clinical loss of response
3. Enable personalized switching thresholds calibrated to individual noise sensitivity profiles rather than population-level cutoffs

Mathematical Framework

Let X_t represent the ASDAS trajectory satisfying the SDE:

Current senolytic strategies indiscriminately clear senescent cells, potentially eliminating crucial wound-healing and tissue-patterning functions [PMC4349629]. The core pathological driver is not the senescent cell itself, but the age-related failure to clear it after its protective work is done PMC4349629. While immune surveillance impairment is observed, the precise mechanism remains elusive.

Hypothesis: Chronic, tonic Type I interferon (IFN-I) signaling, driven by age-related cGAS-STING activation, directly induces a phagocytic arrest in tissue-resident and recruited macrophages. This IFN-I-mediated "clearance paralysis" converts an acute, beneficial senescence response into a chronic, pathological state by preventing macrophage-mediated removal of senescent cells, regardless of their SASP profile.

Novel Mechanistic Reasoning: The established rewiring of immune cells from STAT1 to STAT3 under chronic IFN-I exposure [PMC12432374] is more than a signaling shift—it may reprogram fundamental macrophage effector functions. Specifically:

1. STAT3 Dominance: High STAT3 activity is known to suppress pro-inflammatory and phagocytic gene programs while promoting an anti-inflammatory, fibrotic phenotype. Chronic IFN-I could bias macrophages toward a STAT3-high state that is intrinsically poor at recognizing and engulfing senescent cells.
2. Receptor Interference: IFN-I upregulates inhibitory receptors (e.g., SIRPα) or downregulates "eat-me" signal receptors (e.g., receptors for calreticulin, a potential sene

Hypothesis: Age-related accumulation of mitochondrial DNA (mtDNA) mutations in colonic epithelial stem cells triggers cytosolic release of mtDNA, activating the cGAS-STING pathway and downstream type I interferon signaling. This chronic innate immune activation induces transcriptional upregulation of DNMTs, promoting promoter hypermethylation of MMR genes (MGMT, PMS2, MSH2) and Wnt pathway inhibitors (SFRP2, DKK1, BMP3) in both mutant and adjacent wild-type crypts, creating a field of epigenetically synchronized cells with reduced DNA repair capacity and increased clonal fitness. The resulting MMR-deficient field enables hypermutation while simultaneously selects for stem cells with adaptive advantages, accelerating crypt fission and niche succession.

Mechanistic Reasoning: The research context establishes that inflammation accelerates MMR decline 1 and that field effects extend 10 cm from tumors 2, yet the upstream trigger linking aging to widespread epigenetic silencing remains unclear. Mitochondrial dysfunction represents this missing link. Colonic stem cells exhibit high metabolic demand and continuous exposure to luminal oxidants, rendering them particularly vulnerable to mtDNA accumulation. Unlike nuclear DNA, mtDNA lacks protective histones and efficient repair mechanisms, accumulating mutations at 10-100x the nuclear rate.

With age, mtDNA mutations impair the electron transport chain, increasing mitochondrial ROS production and membrane permeabilit

Hypothesis: Pharmacological senolysis in aged tissues does not merely remove damaged cells; it dismantles a senescent cell-maintained, constitutive interferon signaling network that functions as a critical tumor-suppressive barrier. This leads to a transient reduction in inflammatory markers but a subsequent increase in vulnerability to oncogenic transformation due to loss of chronic interferon-stimulated gene (ISG) expression.

Mechanistic Rationale: Chronic ISG expression in aged tissues, particularly in the liver, is driven by senescent cells and is protective against tumorigenesis under oncogenic stress [GSE313646]. This represents an adaptive immune priming mechanism, not signal exhaustion, potentially maintained via unphosphorylated STAT protein accumulation [PMC4443896]. Senescent cells are the primary source of the SASP factors that sustain this local interferon-rich microenvironment.

Senolytics (e.g., Dasatinib+Quercetin) clear these p16-positive cells [PMC10148948], directly removing the cellular source of the protective SASP. The immediate consequence is a reduction in tissue-level inflammation. However, the downstream effect is the collapse of the constitutive ISG network that provided chronic, low-level tumor surveillance. This creates a window of opportunity for initiated cells to progress. The system trades a controlled, senescence-associated "inflammaging" for a loss of immune vigilance, a classic case of solving one problem (chronic inflammation) by creating a more dangerous one (oncogenic escape).

Testable Predictions:

1. **Aged mice treated

The ACSS2 Paradox: A Phosphorylation-Based Hypothesis

ACSS2 exhibits a tissue-specific duality: in peripheral cells, it promotes senescence by acetylating PAICS, enhancing autophagic degradation and inflammatory cGAS-STING signaling ACSS2 senescence role, while in neurons under AMPK activation or glucose starvation, it translocates to the nucleus to boost HAT activity and support resilience in aging and tauopathy models ACSS2 neuronal resilience. This paradox suggests a regulatory switch that determines ACSS2 localization and function, likely involving post-translational modifications. I propose that AMPK-mediated phosphorylation of ACSS2 at specific serine/threonine residues is the key determinant of its nuclear translocation in neurons, and that age-related decline in AMPK activity disrupts this switch, contributing to epigenetic dysregulation and neuronal aging.

Mechanistic Reasoning: A Phosphorylation-Driven Localization Switch

• AMPK Activation as a Trigger: Under glucose starvation or stress, AMPK is activated and phosphorylates ACSS2, promoting its nuclear import. This is supported by evidence that nuclear ACSS2 enhances HAT activity during nutrient depletion ACSS2 nuclear role. In neurons, this phosphorylation could occur at conserved sites analogous to those in other metabolic enzymes, such as the N-terminal domain, facilitating interaction with nuclear transport machinery.
• **Aging-Induce

Hypothesis: Protective senescent cells maintain tissue homeostasis through stable, broad H3K27me3 domains that suppress oncogenic transcription while secreting context-dependent SASP factors; indiscriminate senolytic clearance erases these epigenetic sentinels, accelerating aging and cancer risk by dismantling a built-in tissue surveillance system.

Mechanistic

Rationale: Epigenetic Encoding of Senescent Cell Fate Senescent cells aren't a monolith. Single-cell RNA-seq reveals SASP-high clusters with pro-inflammatory signatures versus quiescent subsets, but the key differentiator may lie in the chromatin landscape. Aging involves global H3K27me3 redistribution—fewer, broader peaks forming multi-megabase "age-domains" that silence developmental genes [https://pmc.ncbi.nlm.nih.gov/articles/PMC9949032/]. Critically, senescence drives SAHF formation and H3K27me3/H3K9me3 alterations [https://www.jci.org/articles/view/95148], but not uniformly. Protective senescent subpopulations likely retain or even reinforce specific H3K27me3 domains at loci regulating proliferation (e.g., cell-cycle inhibitors like p16) and SASP composition, acting as epigenetic brakes on transformation. Their SASP, under this chromatin control, would be tuned to recruit immune cells for preneoplastic clearance [https://pubmed.ncbi.nlm.nih.gov/29670296/] and promote wound healing via factors like CCN1 [https://www.jci.org/articles/view/95148].

Pathological senescent cells, in contrast, may exhibit eroded H3K27me3 domains due to EZH2 decline [https://www.aging-us.com/article/101617/text], leading